Porovnat metody
Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.
| Fyziologicky založená farmakokinetika× | Korelace in vitro–in vivo× | |
|---|---|---|
| Obor | Farmakologie | Farmakologie |
| Rodina | Process / pipeline | Process / pipeline |
| Rok vzniku≠ | 1997 | 1995 |
| Tvůrce≠ | Ivan Nestorov | Gordon Amidon |
| Typ≠ | predictive modeling | bioavailability prediction |
| Původní zdroj≠ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ | Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-420. DOI ↗ |
| Další názvy≠ | PBPK, PBPK modeling | IVIVC |
| Příbuzné | 3 | 3 |
| Shrnutí≠ | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. | IVIVC is a mathematical relationship between in vitro and in vivo properties of a drug, developed to predict oral bioavailability from dissolution data. Introduced by Amidon and colleagues in the 1995 Biopharmaceutics Classification System, it bridges laboratory measurements and clinical outcomes to streamline drug development. |
| ScholarGateDatová sada ↗ |
|
|